Search: WFRF:(Sjöström Anne Christine)
> (2020-2022) >
Apomorphine formula...
-
Hagell, PeterPatient Reported Outcomes - Clinical Assessment Research and Education (PROCARE),Department of Nursing and Integrated Health Sciences,Avdelningen för sjuksköterskeutbildningarna och integrerad hälsovetenskap,The PRO-CARE Group, Faculty of Health Sciences, Kristianstad University, 291 88, Kristianstad, Sweden
(author)
Apomorphine formulation may influence subcutaneous complications from continuous subcutaneous apomorphine infusion in Parkinson's disease
- Article/chapterEnglish2020
Publisher, publication year, extent ...
-
2020-07-01
-
D. Steinkopff-Verlag,2020
-
6
Numbers
-
LIBRIS-ID:oai:researchportal.hkr.se/admin:publications/c6d20536-28ed-40b7-8f24-00ed69c4a3bb
-
oai:researchportal.hkr.se/admin:publications/c6d20536-28ed-40b7-8f24-00ed69c4a3bbURI
-
https://doi.org/10.1007/s00415-020-10031-1DOI
-
http://kipublications.ki.se/Default.aspx?queryparsed=id:144085273URI
-
https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-174324URI
Supplementary language notes
-
Language:English
-
Summary in:English
Part of subdatabase
Classification
-
Subject category:ref swepub-contenttype
-
Subject category:art swepub-publicationtype
Notes
-
Funding agencies: Open access funding provided by Kristianstad University; Pharmaceuticals Sales andDevelopment Sweden AB.
-
Continuous subcutaneous (s.c.) apomorphine infusion is an effective therapy for Parkinson's disease (PD), but a limitation is the formation of troublesome s.c. nodules. Various chemically non-identical apomorphine formulations are available. Anecdotal experiences have suggested that shifting from one of these (Apo-Go PumpFill®; apoGPF) to another (Apomorphine PharmSwed®; apoPS) may influence the occurrence and severity of s.c. nodules. We, therefore, followed 15 people with advanced PD (median PD-duration, 15 years; median "off"-phase Hoehn and Yahr, IV) on apoGPF and with troublesome s.c. nodules who were switched to apoPS. Data were collected at baseline, at the time of switching, and at a median of 1, 2.5, and 7.3 months post-switch. Total nodule numbers (P < 0.001), size (P < 0.001), consistency (P < 0.001), skin changes (P = 0.058), and pain (P ≤ 0.032) improved over the observation period. PD severity and dyskinesias tended to improve and increase, respectively. Apomorphine doses were stable, but levodopa doses increased by 100 mg/day. Patient-reported apomorphine efficacy tended to increase and all participants remained on apoPS throughout the observation period; with the main patient-reported reason being improved nodules. These observations suggest that patients with s.c. nodules caused by apoGPF may benefit from switching to apoPS in terms of s.c. nodule occurrence and severity. Alternatively, observed benefits may have been due to the switch itself. As nodule formation is a limiting factor in apomorphine treatment, a controlled prospective study comparing local tolerance with different formulations is warranted.
Subject headings and genre
Added entries (persons, corporate bodies, meetings, titles ...)
-
Höglund, ArjaKarolinska Institutet,Department of Neurology, Karolinska University Hospital, Stockholm, Sweden,Karolinska University Hospital,Karolinska Universitetssjukhuset
(author)
-
Hellqvist, Carina,1976-Linköpings universitet,Avdelningen för omvårdnad och reproduktiv hälsa,Medicinska fakulteten,Region Östergötland, Neurologiska kliniken i Linköping,Linköping University Hospital,Universitetssjukhuset i Linköping(Swepub:liu)carhe89
(author)
-
Johansson, Eva-LenaKarlstad Central Hospital,Centralsjukhuset Karlstad,Department of Neurology, Karlstad Central Hospital, Karlstad, Sweden
(author)
-
Löwed, BeritKarlstad Central Hospital,Centralsjukhuset Karlstad,Department of Neurology, Karlstad Central Hospital, Karlstad, Sweden
(author)
-
Sjöström, Anne-ChristineSahlgrenska University Hospital,Department of Neurology, Sahlgrenska University Hospital, Gothenburg, Sweden
(author)
-
Karlberg, CarinaSahlgrenska University Hospital,Department of Neurology, Sahlgrenska University Hospital, Gothenburg, Sweden
(author)
-
Lundgren, MargarethKarolinska University Hospital,Karolinska Universitetssjukhuset,Department of Neurology, Karolinska University Hospital, Stockholm, Sweden
(author)
-
Dizdar, Nil,1960-Linköpings universitet,Avdelningen för neurobiologi,Medicinska fakulteten,Region Östergötland, Neurologiska kliniken i Linköping,Linköping University(Swepub:liu)nildi39
(author)
-
Johansson, AndersKarolinska Institutet,Department of Neurology, Karolinska University Hospital, Stockholm, Sweden,Karolinska University Hospital,Karolinska Universitetssjukhuset
(author)
-
Willows, ThomasKarolinska University Hospital,Karolinska Universitetssjukhuset,Department of Neurology, Karolinska University Hospital, Stockholm, Sweden
(author)
-
Rådberg, JohanKarlstad Central Hospital,Centralsjukhuset Karlstad,Department of Neurology, Karlstad Central Hospital, Karlstad, Sweden
(author)
-
Bergquist, FilipSahlgrenska University Hospital,Department of Neurology, Sahlgrenska University Hospital, Gothenburg, Sweden
(author)
-
Patient Reported Outcomes - Clinical Assessment Research and Education (PROCARE)Department of Nursing and Integrated Health Sciences
(creator_code:org_t)
Related titles
-
In:Journal of Neurology: D. Steinkopff-Verlag267:11, s. 3411-34170340-53541432-1459
Internet link
Find in a library
To the university's database
- By the author/editor
-
Hagell, Peter
-
Höglund, Arja
-
Hellqvist, Carin ...
-
Johansson, Eva-L ...
-
Löwed, Berit
-
Sjöström, Anne-C ...
-
show more...
-
Karlberg, Carina
-
Lundgren, Margar ...
-
Dizdar, Nil, 196 ...
-
Johansson, Ander ...
-
Willows, Thomas
-
Rådberg, Johan
-
Bergquist, Filip
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Health Sciences
-
and Public Health Gl ...
- Articles in the publication
-
Journal of Neuro ...
- By the university
-
Kristianstad University College
-
Karolinska Institutet
-
Linköping University